EcoDrugPlus

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSBSLG00000019399
Gene Symbol: LOC114857944
2 Cross references
186 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSBSLG00000021473
Gene Symbol: LOC114848131
3 Cross references
195 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSBSLG00000018325
Gene Symbol: NPR2
3 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSBSLG00000023421
Gene Symbol: NPR3
3 Cross references
210 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSBSLG00000012905
Gene Symbol: LOC114867060
3 Cross references
195 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSBSLG00000009150
Gene Symbol: LOC114860352
3 Cross references
193 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSBSLG00000000025
Gene Symbol: LOC114854709
3 Cross references
201 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSBSLG00000021098
Gene Symbol: LOC114858858
3 Cross references
195 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSBSLG00000018854
Gene Symbol: LOC114851812
3 Cross references
208 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSBSLG00000000784
Gene Symbol: LOC114862012
2 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSBSLG00000007957
Gene Symbol: LOC114851260
2 Cross references
177 Possible Orthologues:

Neuropeptide Y Receptor Type 4-Like

Ensembl ID : ENSBSLG00000025088
Gene Symbol: LOC114841757
3 Cross references
137 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).